journal article Jul 14, 2017

Comparative effects of liraglutide 3 mg vs structured lifestyle modification on body weight, liver fat and liver function in obese patients with non‐alcoholic fatty liver disease: A pilot randomized trial

Diabetes, Obesity and Metabolism Vol. 19 No. 12 pp. 1814-1817 · Wiley
View at Publisher Save 10.1111/dom.13007
Abstract
We compared the effects of weight loss induced by the glucagon‐like peptide 1‐agonist liraglutide with a structured lifestyle intervention in obese adults with non‐alcoholic fatty liver disease (
NAFLD
). Obese (body mass index ≥30 kg/m
2
, mean weight 96.0 ± 16.3 kg) non‐diabetic Asian adults, with
NAFLD
diagnosed by liver fat fraction (
LFF
) ≥ 5.5% on magnetic resonance imaging without other causes of hepatic steatosis, were randomized to a supervised program of dieting (restriction by 400 kilocalories/d) plus moderate‐intensity aerobic exercise (~200 min/wk;
DE
group,
n
= 12), or liraglutide at the 3 mg daily dose approved for weight loss (
LI
group,
n
= 12), for 26 weeks. Both
DE
and
LI
groups had significant (
P
< .01) and similar reductions in weight (−3.5 ± 3.3 vs −3.5 ± 2.1 kg, respectively,
P
= .72),
LFF
(−8.9 ± 13.4 vs −7.2% ± 7.1%,
P
= .70), serum alanine aminotransferase (−42 ± 46 vs −34 ± 27 U/L,
P
= .52) and aspartate aminotransferase (−23 ± 24 vs −18 ± 15 U/L,
P
= .53). In this first randomized study comparing the 2 weight‐loss modalities for improving
NAFLD
, liraglutide was as effective as structured lifestyle modification.
Topics

No keywords indexed for this article. Browse by subject →

References
18
[5]
Weight Loss Through Lifestyle Modification Significantly Reduces Features of Nonalcoholic Steatohepatitis

Eduardo Vilar-Gomez, Yadina Martinez-Perez, Luis Calzadilla-Bertot et al.

Gastroenterology 10.1053/j.gastro.2015.04.005
[11]
[13]
Petit JM "Effect of liraglutide therapy on liver fat content in patients with inadequately controlled type 2 diabetes. The Lira‐NAFLD study" J Clin Endocrinol Metab (2017)
Cited By
86
NAFLD as a continuum: from obesity to metabolic syndrome and diabetes

Amélio F. Godoy-Matos, Wellington S. Silva Júnior · 2020

Diabetology & Metabolic Syndrom...
Metabolism
Evolution of NAFLD and Its Management

Manpreet S. Mundi, Saketh Velapati · 2019

Nutrition in Clinical Practice
Glucagon-like peptide 1 in health and disease

Andreas Andersen, Asger Lund · 2018

Nature Reviews Endocrinology
Metrics
86
Citations
18
References
Details
Published
Jul 14, 2017
Vol/Issue
19(12)
Pages
1814-1817
License
View
Cite This Article
Joan Khoo, John Hsiang, Ranu Taneja, et al. (2017). Comparative effects of liraglutide 3 mg vs structured lifestyle modification on body weight, liver fat and liver function in obese patients with non‐alcoholic fatty liver disease: A pilot randomized trial. Diabetes, Obesity and Metabolism, 19(12), 1814-1817. https://doi.org/10.1111/dom.13007